Ipsen pulls cancer drug Tazverik from market over safety risksnews2026-03-09T18:16:40+00:00March 9th, 2026|Endpoints News|
Make way, Camzyos: Cytokinetics touts promising early launch for rival heart drugnews2026-02-25T20:17:20+00:00February 25th, 2026|Endpoints News|
Novo Nordisk to slash Wegovy list price in half in 2027 news2026-02-24T20:38:01+00:00February 24th, 2026|Endpoints News|
Despite FDA’s crackdown, pharma is still spending millions on adsnews2026-02-09T16:06:06+00:00February 9th, 2026|Endpoints News|
Takeda ‘anticipated’ Medicare negotiations for top seller Entyvionews2026-01-29T19:06:42+00:00January 29th, 2026|Endpoints News|
Novo’s Wegovy pill off to a solid start after just two weeks on marketnews2026-01-23T20:23:41+00:00January 23rd, 2026|Endpoints News|
CMS unveils IRA prices for Ozempic, Wegovy and other drugs from second roundnews2025-11-25T23:09:56+00:00November 25th, 2025|Endpoints News|
Madrigal CEO welcomes MASH competition from Novo as demand climbs higher for Rezdiffranews2025-11-04T20:25:52+00:00November 4th, 2025|Endpoints News|
Merck CEO touts Winrevair launch, says he’s looking for deals ‘with urgency’news2025-10-30T18:49:30+00:00October 30th, 2025|Endpoints News|
Pfizer, Novartis, BMS, Lilly and others targeted in FDA’s TV ad crackdownnews2025-09-16T19:27:05+00:00September 16th, 2025|Endpoints News|
